-
Article
Identification of time point to best define ‘sub-optimal response’ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data
To determine the average time-point at which it is best to define ‘sub-optimal response’ after ranibizumab treatment for diabetic macular edema (DME) based on the data obtained from real-life clinical practice.
-
Article
Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema
Intraocular vascular endothelial growth factor (VEGF) levels increases with the severity of diabetic retinopathy. Response of diabetic macular oedema (DMO) to ranibizumab is driven by VEGF suppression. We hypo...
-
Article
Response to ‘Comment on Topiramate maculopathy secondary to dose titration: first reported case’
-
Article
Topiramate maculopathy secondary to dose titration: first reported case
-
Article
Using data from the Cataract National Dataset electronic multicentre audit to calculate risk of posterior capsule rupture and vitreous loss for patients on current surgical lists
-
Article
Intravitreal ranibizumab for choroidal neovascularisation secondary to pathologic myopia: 12 month results
-
Article
Realignment of a previously dislocated intraocular lens with a secondary intraocular lens: a rare cause of severe myopia
-
Article
Keratoconus in tuberous sclerosis
-
Article
Eclipse retinopathy
Purpose Solar retinopathy is a well-recognised clinical entity of macular damage caused by viewing the sun, induced by a photochemical process. The term ‘eclipse retinopathy’ is frequently employed when the condi...